donepezil has been researched along with Amentia in 212 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here we conducted a randomized and double-blind study attempting to explore the safety and efficacy of combined therapy of Di-Huang-Yi-Zhi (DHYZ) with donepezil in treating Parkinson's disease dementia (PDD)." | 9.20 | Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia. ( An, H; Gu, C; Liu, T; Shen, T; Wang, X; Ye, Q; Yuan, C; Zhang, T; Zhou, J, 2015) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 9.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 9.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) by means of open label study." | 9.12 | Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. ( Burn, D; Daniel, S; McKeith, IG; Mosimann, U; Newby, J; O'Brien, JT; Rowan, E; Sanders, J; Saxby, BK; Wesnes, K, 2007) |
| "The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD)." | 9.12 | Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. ( Licht, E; McMurtray, A; Mendez, MF; Shapira, JS, 2007) |
| "To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD)." | 9.11 | Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. ( Crawley, A; Farrar, JT; Fernandez, HH; Gillespie, M; Putt, M; Ravina, B; Reichwein, S; Siderowf, A; Simuni, T; Trieschmann, MM, 2005) |
| "This open label study was designed to assess the effects of donepezil treatment, its withdrawal and subsequent recommencement on cognitive functioning, behaviour and parkinsonian symptoms in patients with probable dementia with Lewy bodies (DLB) and with Parkinson's disease who subsequently developed dementia (PDD)." | 9.10 | What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. ( Daniel, SL; Littlewood, E; McKeith, IG; Minett, TS; Myint, P; Newby, J; Richardson, J; Sanders, J; Thomas, A; Wilkinson, LM, 2003) |
| "To review the evidence for the effectiveness of cholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and the neuropeptide-modifying agent memantine in achieving clinically relevant improvements, primarily in cognition, global function, behavior, and quality of life, for patients with dementia." | 8.84 | Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. ( Booker, L; Cowan, D; Ismaila, A; Levine, M; Oremus, M; Patterson, C; Raina, P; Santaguida, P, 2008) |
| "We utilized the Medical Information Mart for Intensive Care III (MIMIC-III) database to determine whether pre-hospital donepezil use was associated with improved outcomes during critical illness in dementia patients." | 8.31 | Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium. ( Lee, S; Lieberman, OJ; Zabinski, J, 2023) |
| "Donepezil seems to decrease in-hospital mortality as a result of pneumonia among older patients with dementia." | 7.88 | Donepezil is associated with decreased in-hospital mortality as a result of pneumonia among older patients with dementia: A retrospective cohort study. ( Abe, Y; Fushimi, K; Shimokado, K, 2018) |
| "The clinical response to donepezil in patients with mild and moderate dementia was investigated in relation to the drug plasma concentration and APOE and CYP2D6 polymorphisms." | 7.85 | Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms. ( Assini, AG; Byrro, RM; Caramelli, P; Gomes, KB; Miranda, LF; Moraes, EN; Peles, PR; Pereira, FH; Pianetti, GA; Ribeiro, VV; Santos, TR; Silveira, JN; Tito, PA, 2017) |
| " We enrolled 24 patients with DLB (diagnosed according to the Consortium on Dementia with Lewy Bodies Guideline-Revised) who experienced a relapse of BPSD despite treatment with donepezil at the standard dose (5 mg/day)." | 7.83 | Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. ( Ino, T; Kosaka, K; Manabe, Y; Yamanaka, K, 2016) |
| "The present study investigates the anti-amnesic potential of clioquinol (5-chloro-7-iodoquinolin-8-ol) in cognitive deficits associated with experimental dementia induced by Cu-Ch." | 7.81 | Memory restorative ability of clioquinol in copper-cholesterol-induced experimental dementia in mice. ( Aggarwal, N; Mehra, R; Sodhi, RK, 2015) |
| "In patients with mild dementia who had received donepezil and cilostazol (n = 34; 77." | 7.80 | Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. ( Hattori, Y; Ihara, M; Kasahara, Y; Nishino, M; Okada, M; Saito, S; Taguchi, A; Takahashi, Y; Takata, Y; Tsuji, M; Yamamoto, Y, 2014) |
| "The present results suggest that treatment with dose escalation of donepezil from 5 mg/day to 10 mg/day may be therapeutically useful for patients with Parkinson's disease with dementia who have taken donepezil 5 mg/day in the long term." | 7.80 | Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study. ( Hattori, N; Ishikawa, K; Kubo, S; Mizuno, Y; Motoi, Y, 2014) |
| "Although donepezil, an acetylcholinesterase inhibitor, has been proved to be effective in ameliorating cognitive impairment in Parkinson's disease with dementia (PDD), the responsiveness of patients to donepezil therapy varies." | 7.78 | Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia. ( Fujii, T; Funaki, Y; Hayashi, A; Hiraoka, K; Hisanaga, K; Iwata, R; Mori, E; Okamura, N; Takeda, A; Tashiro, M; Yanai, K, 2012) |
| "To demonstrate the safety and tolerability of galantamine SA in dementia patients transitioned from donepezil." | 7.77 | Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil. ( Berlowitz, DR; Brown, J; Budson, AE; Rosenbloom, MH, 2011) |
| " Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 7.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
| "It has been reported that the cholinesterase inhibitor, donepezil, improves cognitive decline in patients with Parkinson's disease dementia (PDD)." | 7.74 | The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia. ( Imamura, K; Kowa, H; Nakashima, K; Tanabe, Y; Wada-Isoe, K, 2008) |
| " Therefore, the present study was designed to investigate the influence of antidementia drugs, tacrine and donepezil, on biochemical markers of oxidative stress, glutathione (GSH) and malondialdehyde (MDA), and acetylcholinesterase activity in the brain in a streptozotocin-induced experimental model of dementia in mice." | 7.74 | Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. ( Agrawal, R; Nath, C; Saxena, G; Singh, SP, 2008) |
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 7.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 7.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "The goal of this study was to investigate whether donepezil treatment is associated with reduced mortality in nursing home residents who have dementia." | 7.73 | Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? ( Gasper, MC; Lapane, KL; Ott, BR, 2005) |
| "The purpose of this study was to estimate the impact of donepezil use on health care costs and utilization in patients with mild to moderate AD and related dementias." | 7.73 | Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. ( Fillit, H; Hill, J; Lu, S, 2005) |
| "Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)." | 7.72 | Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003) |
| " Adverse events were more common with donepezil but mostly mild/moderate in severity." | 6.77 | Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. ( Dubois, B; Emre, M; Gray, J; Hsu, T; Katzenschlager, R; Lees, AJ; Moline, ML; Pourcher, E; Schumann, G; Swartz, J; Thomas, G; Tolosa, E, 2012) |
| "Treatment with donepezil was only effective in PD patients with dementia, who experience nearly no side effects from the drug." | 6.72 | The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. ( Baas, H; Ebersbach, G; Fuchs, G; Müller, T; Reichmann, H; Welnic, J, 2006) |
| "Treatment with donepezil was sometimes associated with worse parkinsonism." | 6.69 | Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. ( MacKnight, C; Rockwood, K; Shea, C, 1998) |
| "It is shown that dementia is a risk factor for falls, and standard measures to prevent falls in the elderly are ineffective in patients with cognitive impairment." | 6.61 | [The use of donepezil in gait disorders in eldery patients with dementia]. ( Chebotareva, AD; Dudchenko, NG, 2019) |
| "When donepezil was re-prescribed, the delirium resolved and the patient's mental state stabilized." | 5.38 | Withdrawal syndrome after donepezil cessation in a patient with dementia. ( Bidzan, L; Bidzan, M, 2012) |
| "Delirium is a common complication of dementia and may produce considerable morbidity." | 5.30 | Donepezil improves symptoms of delirium in dementia: implications for future research. ( Burke, WJ; Roccaforte, WH; Wengel, SP, 1998) |
| " Studies in early radiotherapy treatment phase (five studies) Pharmacological studies in the "early radiotherapy treatment phase" were designed to prevent or ameliorate cognitive deficits and included drugs used in dementia (memantine) and fatigue (d-threo-methylphenidate hydrochloride)." | 5.22 | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. ( Brown, PD; Day, J; Gehring, K; Grosshans, D; Kirkman, MA; Li, J; Taphoorn, M; Zienius, K, 2022) |
| "6% (n = 72) of participants received antidementia drugs: memantine 44." | 5.20 | Antidementia drug treatment in people screened positive for dementia in primary care. ( Eichler, T; Hertel, J; Hoffmann, W; Kilimann, I; Michalowsky, B; Teipel, S; Thyrian, JR; Wucherer, D, 2015) |
| "Here we conducted a randomized and double-blind study attempting to explore the safety and efficacy of combined therapy of Di-Huang-Yi-Zhi (DHYZ) with donepezil in treating Parkinson's disease dementia (PDD)." | 5.20 | Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia. ( An, H; Gu, C; Liu, T; Shen, T; Wang, X; Ye, Q; Yuan, C; Zhang, T; Zhou, J, 2015) |
| "To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes." | 5.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "Donepezil does not seem to improve negative signs and cognitive impairment in elderly patients with chronic schizophrenia." | 5.12 | Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. ( Barak, Y; Mazeh, D; Mirecki, I; Paleacu, D; Zemishlani, H, 2006) |
| "We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) by means of open label study." | 5.12 | Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. ( Burn, D; Daniel, S; McKeith, IG; Mosimann, U; Newby, J; O'Brien, JT; Rowan, E; Sanders, J; Saxby, BK; Wesnes, K, 2007) |
| "The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD)." | 5.12 | Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. ( Licht, E; McMurtray, A; Mendez, MF; Shapira, JS, 2007) |
| "A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia." | 5.12 | Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. ( Clark, CM; DeCarli, C; Frisoni, GB; Grundman, M; Harvey, D; Jack, CR; Jin, S; Petersen, RC; Scheltens, P; Thal, LJ, 2007) |
| "To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD)." | 5.11 | Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. ( Brandt, J; Grill, S; Leroi, I; Lyketsos, CG; Marsh, L; Reich, SG; Thompson, R, 2004) |
| "To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD)." | 5.11 | Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. ( Crawley, A; Farrar, JT; Fernandez, HH; Gillespie, M; Putt, M; Ravina, B; Reichwein, S; Siderowf, A; Simuni, T; Trieschmann, MM, 2005) |
| "This open label study was designed to assess the effects of donepezil treatment, its withdrawal and subsequent recommencement on cognitive functioning, behaviour and parkinsonian symptoms in patients with probable dementia with Lewy bodies (DLB) and with Parkinson's disease who subsequently developed dementia (PDD)." | 5.10 | What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. ( Daniel, SL; Littlewood, E; McKeith, IG; Minett, TS; Myint, P; Newby, J; Richardson, J; Sanders, J; Thomas, A; Wilkinson, LM, 2003) |
| "Donepezil, galantamine, and rivastigmine are the three acetylcholinesterase inhibitors (AChEIs), out of a total of only four medications prescribed in the treatment of Alzheimer's Disease (AD) and related dementias." | 5.05 | Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review. ( Alsabbagh, MW; Huang, Y, 2020) |
| " Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation." | 4.93 | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. ( Barrantes, FJ; Peralta, MC; Perez-Lloret, S, 2016) |
| "Some randomized studies, mostly of short duration, have indicated that cholinesterase inhibitors (donepezil, rivastigmine and galantamine) may have a beneficial effect in Alzheimer's disease, vascular dementia and in dementia caused by Lewy body disease." | 4.84 | [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]. ( Landmark, K; Reikvam, A, 2008) |
| "To review the evidence for the effectiveness of cholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and the neuropeptide-modifying agent memantine in achieving clinically relevant improvements, primarily in cognition, global function, behavior, and quality of life, for patients with dementia." | 4.84 | Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. ( Booker, L; Cowan, D; Ismaila, A; Levine, M; Oremus, M; Patterson, C; Raina, P; Santaguida, P, 2008) |
| "We utilized the Medical Information Mart for Intensive Care III (MIMIC-III) database to determine whether pre-hospital donepezil use was associated with improved outcomes during critical illness in dementia patients." | 4.31 | Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium. ( Lee, S; Lieberman, OJ; Zabinski, J, 2023) |
| " The study included older adults (aged 65 and older) with a diagnosis of dementia using donepezil, galantamine, or rivastigmine." | 4.12 | Risk of overactive bladder associated with cholinesterase inhibitors in dementia. ( Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML; Masurkar, PP; Sherer, JT, 2022) |
| "We used Pharmaceutical Benefits Scheme dispensing claims to identify patients who initiated donepezil, rivastigmine, galantamine or memantine between 1 January 2013 and 30 June 2017 (after a period of ≥180 days with no dispensing of these medicines) and remained on therapy for ≥180 days (n = 4393), and dispensed anticholinergic medicines in the 180 days before and after initiating dementia medicines." | 3.91 | Anticholinergic medicines use among older adults before and after initiating dementia medicines. ( Buckley, N; Le Couteur, DG; Litchfield, M; McLachlan, AJ; Narayan, SW; Pearson, SA; Zoega, H, 2019) |
| "Donepezil seems to decrease in-hospital mortality as a result of pneumonia among older patients with dementia." | 3.88 | Donepezil is associated with decreased in-hospital mortality as a result of pneumonia among older patients with dementia: A retrospective cohort study. ( Abe, Y; Fushimi, K; Shimokado, K, 2018) |
| "BACKGROUND The aim of this study was to investigate the effects of oxygen and cholinesterase inhibitor (donepezil) therapy on dementia in patients with age-exacerbated chronic obstructive pulmonary disease (COPD) in China's northwestern high-altitude area." | 3.88 | Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area. ( Li, H; Mei, L; Wang, D; Wang, M; Wu, S; Zhang, H, 2018) |
| "This study is a retrospective review of patients hospitalized from 1 January 2006 to 31 December 2010 at a general hospital who simultaneously received US Food and Drug Administration-approved dementia medications (galantamine, rivastigmine, donepezil, and/or memantine) and anticholinergics." | 3.85 | Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders. ( Goebert, D; Guilloux, A; Higa, J; Lu, BY; Schultz, BR; Takeshita, J; Takeshita, S, 2017) |
| "The clinical response to donepezil in patients with mild and moderate dementia was investigated in relation to the drug plasma concentration and APOE and CYP2D6 polymorphisms." | 3.85 | Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms. ( Assini, AG; Byrro, RM; Caramelli, P; Gomes, KB; Miranda, LF; Moraes, EN; Peles, PR; Pereira, FH; Pianetti, GA; Ribeiro, VV; Santos, TR; Silveira, JN; Tito, PA, 2017) |
| " We enrolled 24 patients with DLB (diagnosed according to the Consortium on Dementia with Lewy Bodies Guideline-Revised) who experienced a relapse of BPSD despite treatment with donepezil at the standard dose (5 mg/day)." | 3.83 | Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. ( Ino, T; Kosaka, K; Manabe, Y; Yamanaka, K, 2016) |
| "To characterize pediatric exposures to the antidementia drugs donepezil, memantine, rivastigmine, and galantamine by reviewing a poison control system's database." | 3.83 | Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System. ( Cantrell, FL; Pchelnikova, JL; Thornton, SL, 2016) |
| "AchEI therapy has no unfavorable effect on nutritional status or weight in elderly patients with different types of dementia, but it seems that food intake is better in those treated by rivastigmine patch." | 3.83 | Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study. ( Isik, AT; Soysal, P, 2016) |
| "In the observed period (2012-2014), 4568 patients were treated with anti-dementia medications, of which 1275 (32%) with donepezil, and 2753 (68%) with memantine." | 3.83 | Epidemiological Characteristics of Dementia Treatment in Croatia. ( Bielen, I; Draganić, P; Klepac, N; Košćak, J; Sremec, J; Tomasović, S, 2016) |
| "Patients suffering from Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies can be treated well with the cholinesterase inhibitors rivastigmine or donepezil, and because of the increasing number of these patients undergoing surgery in general anaesthesia we find it urgent to draw attention to possible complications such as severe bradycardia or third-degree heart block when propofol and remifentanil are being used." | 3.81 | [Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia]. ( Ferguson, AH; Jellinge, ME, 2015) |
| "The present study investigates the anti-amnesic potential of clioquinol (5-chloro-7-iodoquinolin-8-ol) in cognitive deficits associated with experimental dementia induced by Cu-Ch." | 3.81 | Memory restorative ability of clioquinol in copper-cholesterol-induced experimental dementia in mice. ( Aggarwal, N; Mehra, R; Sodhi, RK, 2015) |
| "To compare the risk of pneumonia in older adults receiving donepezil, galantamine, or rivastigmine for dementia." | 3.81 | Risk of pneumonia in new users of cholinesterase inhibitors for dementia. ( Hsieh, CY; Iwata, I; Kao Yang, YH; Lai, EC; Setoguchi, S; Wong, MB; Zhang, Y, 2015) |
| " We included all community-dwelling seniors who had a code for dementia and were exposed to cholinesterase inhibitors (donezepil, galantamine, and rivastigmine) and/or drugs used to treat co-morbidities of hypertension, diabetes, depression and hypothyroidism." | 3.81 | The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada. ( Huang, AR; Redpath, CJ; van Walraven, C, 2015) |
| "In patients with mild dementia who had received donepezil and cilostazol (n = 34; 77." | 3.80 | Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. ( Hattori, Y; Ihara, M; Kasahara, Y; Nishino, M; Okada, M; Saito, S; Taguchi, A; Takahashi, Y; Takata, Y; Tsuji, M; Yamamoto, Y, 2014) |
| "The present results suggest that treatment with dose escalation of donepezil from 5 mg/day to 10 mg/day may be therapeutically useful for patients with Parkinson's disease with dementia who have taken donepezil 5 mg/day in the long term." | 3.80 | Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study. ( Hattori, N; Ishikawa, K; Kubo, S; Mizuno, Y; Motoi, Y, 2014) |
| "All four dementia drugs available on the Swedish market (three cholinesterase inhibitors [donepezil, rivastigmine and galantamine] and memantine) were prescribed at the two dementia clinics." | 3.79 | Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres. ( Johnell, K; Sonde, L, 2013) |
| "Although donepezil, an acetylcholinesterase inhibitor, has been proved to be effective in ameliorating cognitive impairment in Parkinson's disease with dementia (PDD), the responsiveness of patients to donepezil therapy varies." | 3.78 | Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia. ( Fujii, T; Funaki, Y; Hayashi, A; Hiraoka, K; Hisanaga, K; Iwata, R; Mori, E; Okamura, N; Takeda, A; Tashiro, M; Yanai, K, 2012) |
| "To demonstrate the safety and tolerability of galantamine SA in dementia patients transitioned from donepezil." | 3.77 | Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil. ( Berlowitz, DR; Brown, J; Budson, AE; Rosenbloom, MH, 2011) |
| " Furthermore, we evaluated the effect of anti-dementia drugs memantine, a NMDA antagonist, and donepezil, a cholinesterase inhibitor, on OKA ICV induced memory impairment." | 3.76 | Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. ( Kamat, PK; Nath, C; Saxena, G; Shukla, R; Tota, S, 2010) |
| "Cox proportional hazards with time-dependent exposures were used to evaluate the association and examine the dose effect for donepezil and bradycardia." | 3.75 | Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. ( Cantor, MD; Farwell, W; Hernandez, RK; Lawler, EV, 2009) |
| "It has been reported that the cholinesterase inhibitor, donepezil, improves cognitive decline in patients with Parkinson's disease dementia (PDD)." | 3.74 | The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia. ( Imamura, K; Kowa, H; Nakashima, K; Tanabe, Y; Wada-Isoe, K, 2008) |
| " Therefore, the present study was designed to investigate the influence of antidementia drugs, tacrine and donepezil, on biochemical markers of oxidative stress, glutathione (GSH) and malondialdehyde (MDA), and acetylcholinesterase activity in the brain in a streptozotocin-induced experimental model of dementia in mice." | 3.74 | Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. ( Agrawal, R; Nath, C; Saxena, G; Singh, SP, 2008) |
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 3.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 3.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "The goal of this study was to investigate whether donepezil treatment is associated with reduced mortality in nursing home residents who have dementia." | 3.73 | Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? ( Gasper, MC; Lapane, KL; Ott, BR, 2005) |
| "The purpose of this study was to estimate the impact of donepezil use on health care costs and utilization in patients with mild to moderate AD and related dementias." | 3.73 | Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. ( Fillit, H; Hill, J; Lu, S, 2005) |
| "Memantine, a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be effective in dementia, including Alzheimer disease (AD)." | 3.72 | Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. ( Hartmann, S; Möbius, HJ, 2003) |
| "To compare the prevalence of anticholinergic use in older adults with probable dementia with that of a matched comparison group of older adults who were unlikely to have dementia and to examine the extent to which patients taking donepezil concomitantly use anticholinergic medications." | 3.71 | Use of anticholinergic medications by older adults with dementia. ( Anderson, MJ; Roe, CM; Spivack, B, 2002) |
| "Risperidone was also found to be more efficacious than placebo (SMD -0." | 2.82 | Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis. ( Chen, KL; Chen, SD; Dong, Q; Dou, KX; Huang, YY; Shen, XN; Tan, L; Teng, T; Wang, J; Wang, RZ; Yu, JT; Zhang, RQ; Zhao, QH; Zhong, XL; Zhou, XY, 2022) |
| "Studies on potential treatments for dementia in this population are still scarce." | 2.82 | Pharmacological Approaches to the Treatment of Dementia in Down Syndrome: A Systematic Review of Randomized Clinical Studies. ( de Oliveira, LC; de Paula Faria, D, 2022) |
| " Adverse events were more common with donepezil but mostly mild/moderate in severity." | 2.77 | Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. ( Dubois, B; Emre, M; Gray, J; Hsu, T; Katzenschlager, R; Lees, AJ; Moline, ML; Pourcher, E; Schumann, G; Swartz, J; Thomas, G; Tolosa, E, 2012) |
| " An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit." | 2.73 | Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. ( Cummings, J; Kurlan, R; Raman, R; Thal, L, 2007) |
| "Treatment with donepezil was only effective in PD patients with dementia, who experience nearly no side effects from the drug." | 2.72 | The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. ( Baas, H; Ebersbach, G; Fuchs, G; Müller, T; Reichmann, H; Welnic, J, 2006) |
| "A study was performed on patients with Alzheimer's disease (AD) in order to evaluate the efficacy of a combined treatment (donepezil plus cognitive training) in both cognitive processes and affective states." | 2.71 | Effects of cholinergic drugs and cognitive training on dementia. ( Campo, P; López Ibor, JJ; López Ibor, MI; Maestú, F; Ortiz, T; Requena, C, 2004) |
| "Donepezil was well tolerated." | 2.71 | Cholinergic treatment of amnesia following basal forebrain lesion due to aneurysm rupture--an open-label pilot study. ( Benke, T; Delazer, M; Kemmler, G; Köylü, B; Trinka, E, 2005) |
| "Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients." | 2.70 | Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. ( Bharucha, A; Chew, ML; Huber, KA; Jacob, NJ; Kastango, KB; Marin, R; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J; Sweet, RA, 2002) |
| "Treatment with donepezil was sometimes associated with worse parkinsonism." | 2.69 | Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. ( MacKnight, C; Rockwood, K; Shea, C, 1998) |
| "It is shown that dementia is a risk factor for falls, and standard measures to prevent falls in the elderly are ineffective in patients with cognitive impairment." | 2.61 | [The use of donepezil in gait disorders in eldery patients with dementia]. ( Chebotareva, AD; Dudchenko, NG, 2019) |
| "Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment." | 2.58 | The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis. ( Chang, YC; Perng, CH; Tzang, RF, 2018) |
| " Acetylcholinesterase inhibitors (AChEIs) aim to provide symptomatic benefit for cognitive decline, however these drugs are not without adverse events (AEs)." | 2.55 | Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. ( Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D, 2017) |
| "The most prevalent of all dementias is Alzheimer's disease, a progressive neurodegenerative disease that presents with deficits in memory, cognition, motor skills, and a general decline in the quality of life." | 2.55 | Alzheimer's disease in the zebrafish: where can we take it? ( Caramillo, EM; Echevarria, DJ, 2017) |
| "Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD)." | 2.53 | Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. ( Lewis, SJ; Szeto, JY, 2016) |
| "Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes." | 2.49 | Atypical aging in Down syndrome. ( Zigman, WB, 2013) |
| "Mixed dementia is caused by the combination of several simultaneous pathological processes, e." | 2.49 | [Cholinesterase inhibitors in the treatment of mixed dementia]. ( Vasenina, EE, 2013) |
| "Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs." | 2.48 | Reviewing the role of donepezil in the treatment of Alzheimer's disease. ( Cummings, JL; Doody, RS; Farlow, MR, 2012) |
| "Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are the two most common types of dementing neurodegenerative disease after Alzheimer's disease (AD)." | 2.46 | Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. ( Deuschl, G; Förstl, H; Mollenhauer, B; Oertel, W; Storch, A; Trenkwalder, C, 2010) |
| "Studies on Alzheimer's disease and Lewy body dementias show that cholinesterase inhibitors are still first line treatment for these diseases and memantine is indicated in moderate/severe Alzheimer's disease, whereas there is as yet no standard available treatment for frontotemporal dementias." | 2.44 | Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence? ( Engelhardt, E; Laks, J, 2008) |
| " The author provides information on recommended dosing for all three medications, noting that cholinesterase inhibitors must be titrated carefully." | 2.43 | Cholinesterase inhibitors in the treatment of dementia. ( Ellis, JM, 2005) |
| "Donepezil (Aricept) is a highly selective acetylcholinesterase inhibitors with a pharmacokinetic profile allowing once-daily dosing." | 2.42 | Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. ( Geldmacher, DS, 2004) |
| "Cholinesterase inhibitors (ChEIs) are dosed in two phases for the treatment of dementia, an initial dose-escalation phase to achieve a therapeutic dose and a maintenance phase where the therapeutic dose is given for long-term therapy." | 2.41 | The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. ( Inglis, F, 2002) |
| "Treatment approaches to memory loss typically use Alzheimer's dementia as the template, and are discussed in this report." | 2.41 | Approaches to memory loss in neuropsychiatric disorders. ( Devi, G; Silver, J, 2000) |
| "Dementia is a common feature in Parkinson's disease (PD); however, data on dementia treatment patterns in patients with PD are scarce." | 1.72 | Patterns of dementia treatment in older adults with Parkinson's disease using nationwide medical claims data. ( Kim, HJ; Yoon, B, 2022) |
| "All 8 patients had mild cognitive impairment including 6 with amnestic, multidomain impairment." | 1.72 | Effectiveness of an integrative medicine approach to improve cognitive dysfunction and dementia: An observational study. ( Kang, H; Kim, DY; Kim, KK; Kim, MG; Koo, BS; Lee, JH; Shin, HW, 2022) |
| "Dementia was diagnosed in 132 (32." | 1.56 | Dementia Diagnoses and Treatment in Geriatric Ward Patients: A Cross-Sectional Study in Poland. ( Wojszel, ZB, 2020) |
| "Dementia was classified into vascular (VaD) and degenerative dementia." | 1.42 | The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan. ( Chou, YJ; Chow, LH; Hu, HY; Huang, N; Li, CP; Wang, PN; Wu, CY, 2015) |
| "This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia." | 1.42 | Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. ( Abagyan, R; Ali, TB; Chen, WY; Reilly, BM; Schleret, TR, 2015) |
| " Demographic variables, quantity and rate of prescriptions, dosage forms and strengths were analyzed." | 1.39 | [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina]. ( Arizaga, RL; Demey, I; Rojas, G, 2013) |
| "When donepezil was re-prescribed, the delirium resolved and the patient's mental state stabilized." | 1.38 | Withdrawal syndrome after donepezil cessation in a patient with dementia. ( Bidzan, L; Bidzan, M, 2012) |
| "Memantine was also associated with greater risk of all-cause mortality in the Medicare (HR = 1." | 1.38 | Comparative cardiovascular safety of dementia medications: a cross-national study. ( Curtis, LH; Fosbøl, EL; Gislason, GH; Holm, E; Iwata, I; Køber, L; Peterson, ED; Setoguchi, S; Torp-Pedersen, C; Zhang, Y, 2012) |
| "Older age, longer time between Alzheimer's disease diagnosis and first ChEI dispensing, lower dose of ChEI at treatment initiation and the presence of baseline depression and neuropsychiatric symptoms were associated with a significantly increased likelihood of antipsychotic drug use." | 1.36 | Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. ( Duh, MS; Kahler, KH; Lefebvre, P; Mody-Patel, N; Scharre, DW; Vekeman, F, 2010) |
| "Donepezil was used by more than 60% of patients using a single ChI and represented almost 50% of reimbursements for patients that had used at least two different ChIs during the year." | 1.35 | Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. ( Dartigues, JF; Fourrier-Réglat, A; Helmer, C; Merliere, Y; Moore, N; Pariente, A, 2008) |
| "Dementia was diagnosed in 134, and specifically Alzheimer's disease (AD) in 79, by an expert consensus panel." | 1.35 | Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. ( Baker, AS; Brandt, J; Lyketsos, CG; Mayer, LS; McNabney, M; Onyike, CU; Rosenblatt, A; Samus, QM, 2008) |
| "Dementia was induced in Swiss albino mice by administration of Celecoxib (100 mg kg(-1) orally, daily for 9 days) or Streptozotocin (3 mg kg(-1) administered intracerebroventricularly on 1st and 3rd day) and the cognitive behaviors of Swiss albino mice were assessed using Morris water maze test." | 1.35 | Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. ( Jaggi, AS; Sharma, B; Singh, M; Singh, N, 2008) |
| "Inflammation has been recently implicated in pathogenesis of dementia disorders." | 1.34 | Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. ( Agrawal, R; Nath, C; Shukla, R; Tyagi, E, 2007) |
| "Donepezil 10 mg/day was begun." | 1.33 | Improvement in Tc-99m HMPAO brain SPECT findings during donepezil therapy in a patient with pure akinesia. ( Akdal, G; Kaya, GC; Oztürk, V; Yener, GG, 2005) |
| "Delirium is a common complication of dementia and may produce considerable morbidity." | 1.30 | Donepezil improves symptoms of delirium in dementia: implications for future research. ( Burke, WJ; Roccaforte, WH; Wengel, SP, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (8.96) | 18.2507 |
| 2000's | 102 (48.11) | 29.6817 |
| 2010's | 74 (34.91) | 24.3611 |
| 2020's | 17 (8.02) | 2.80 |
| Authors | Studies |
|---|---|
| Washida, K | 1 |
| Kitajima, E | 1 |
| Tanaka, T | 2 |
| Ikeda, S | 1 |
| Chiba, T | 1 |
| Noda, K | 1 |
| Yoshimoto, T | 1 |
| Fukuma, K | 1 |
| Saito, S | 2 |
| Ihara, M | 2 |
| Masurkar, PP | 1 |
| Chatterjee, S | 1 |
| Sherer, JT | 1 |
| Chen, H | 1 |
| Johnson, ML | 1 |
| Aparasu, RR | 1 |
| Huang, YY | 1 |
| Teng, T | 1 |
| Shen, XN | 1 |
| Chen, SD | 1 |
| Wang, RZ | 1 |
| Zhang, RQ | 1 |
| Dou, KX | 1 |
| Zhong, XL | 1 |
| Wang, J | 1 |
| Chen, KL | 1 |
| Zhao, QH | 1 |
| Tan, L | 1 |
| Dong, Q | 1 |
| Zhou, XY | 1 |
| Yu, JT | 1 |
| Yoon, B | 1 |
| Kim, HJ | 1 |
| Parsons, C | 1 |
| Lim, WY | 1 |
| Loy, C | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Ward, SA | 1 |
| Hughes, C | 1 |
| de Oliveira, LC | 1 |
| de Paula Faria, D | 1 |
| Lee, JH | 1 |
| Kim, MG | 1 |
| Kim, DY | 1 |
| Shin, HW | 1 |
| Kang, H | 1 |
| Koo, BS | 1 |
| Kim, KK | 1 |
| Lieberman, OJ | 1 |
| Lee, S | 1 |
| Zabinski, J | 1 |
| Kirkman, MA | 3 |
| Day, J | 3 |
| Gehring, K | 3 |
| Zienius, K | 3 |
| Grosshans, D | 3 |
| Taphoorn, M | 3 |
| Li, J | 3 |
| Brown, PD | 3 |
| Burke, JF | 1 |
| Kerber, KA | 1 |
| Langa, KM | 1 |
| Albin, RL | 1 |
| Kotagal, V | 1 |
| Chebotareva, AD | 1 |
| Dudchenko, NG | 1 |
| Govind, N | 1 |
| Barthold, D | 1 |
| Joyce, G | 1 |
| Ferido, P | 1 |
| Drabo, EF | 1 |
| Marcum, ZA | 1 |
| Gray, SL | 1 |
| Zissimopoulos, J | 1 |
| Huang, Y | 1 |
| Alsabbagh, MW | 1 |
| Knakker, B | 1 |
| Oláh, V | 1 |
| Trunk, A | 1 |
| Lendvai, B | 1 |
| Lévay, G | 1 |
| Hernádi, I | 1 |
| Wojszel, ZB | 1 |
| Murchison, CF | 1 |
| Kennedy, RE | 1 |
| McConathy, JE | 1 |
| Roberson, ED | 1 |
| Kim, DH | 1 |
| Li, X | 1 |
| Bian, S | 1 |
| Wei, LJ | 1 |
| Sun, R | 1 |
| Schultz, BR | 1 |
| Takeshita, J | 1 |
| Goebert, D | 1 |
| Takeshita, S | 1 |
| Lu, BY | 1 |
| Guilloux, A | 1 |
| Higa, J | 1 |
| Tung, EE | 1 |
| Litin, SC | 1 |
| Bundrick, JB | 1 |
| Mohammad, D | 1 |
| Chan, P | 1 |
| Bradley, J | 1 |
| Lanctôt, K | 1 |
| Herrmann, N | 2 |
| Abe, Y | 1 |
| Shimokado, K | 1 |
| Fushimi, K | 1 |
| Perng, CH | 1 |
| Chang, YC | 1 |
| Tzang, RF | 1 |
| Mukku, SSR | 1 |
| Achary, U | 1 |
| Sivakumar, PT | 1 |
| Varghese, M | 1 |
| Mei, L | 1 |
| Wu, S | 1 |
| Wang, D | 1 |
| Li, H | 1 |
| Zhang, H | 1 |
| Wang, M | 1 |
| Narayan, SW | 1 |
| Pearson, SA | 1 |
| Litchfield, M | 1 |
| Le Couteur, DG | 1 |
| Buckley, N | 1 |
| McLachlan, AJ | 1 |
| Zoega, H | 1 |
| Calvo-Torres, LF | 1 |
| Bernal-Cobo, R | 1 |
| Trujillo-Quintero, PM | 1 |
| Gaviria-Mendoza, A | 1 |
| Machado-Alba, JE | 1 |
| Niznik, JD | 1 |
| Zhao, X | 1 |
| He, M | 1 |
| Aspinall, SL | 1 |
| Hanlon, JT | 1 |
| Nace, D | 1 |
| Thorpe, JM | 1 |
| Thorpe, CT | 1 |
| Sonde, L | 1 |
| Johnell, K | 1 |
| Nguyen, ND | 1 |
| Osterweil, D | 1 |
| Hoffman, J | 1 |
| Rojas, G | 1 |
| Demey, I | 1 |
| Arizaga, RL | 1 |
| de Medeiros, K | 1 |
| Basting, A | 1 |
| Rockwood, K | 2 |
| Mitnitski, A | 1 |
| Black, SE | 1 |
| Richard, M | 1 |
| Defoy, I | 1 |
| Zigman, WB | 1 |
| Vasenina, EE | 1 |
| Cumbo, E | 1 |
| Ligori, LD | 1 |
| Nishino, M | 1 |
| Taguchi, A | 1 |
| Yamamoto, Y | 1 |
| Hattori, Y | 1 |
| Takahashi, Y | 1 |
| Tsuji, M | 1 |
| Kasahara, Y | 1 |
| Takata, Y | 1 |
| Okada, M | 1 |
| Igeta, H | 1 |
| Suzuki, Y | 1 |
| Tajiri, M | 1 |
| Someya, T | 1 |
| Ishikawa, K | 1 |
| Motoi, Y | 1 |
| Mizuno, Y | 1 |
| Kubo, S | 1 |
| Hattori, N | 1 |
| Shoji, M | 1 |
| Fujii, M | 1 |
| Sasaki, H | 2 |
| Wucherer, D | 2 |
| Eichler, T | 1 |
| Kilimann, I | 1 |
| Hertel, J | 2 |
| Michalowsky, B | 2 |
| Thyrian, JR | 2 |
| Teipel, S | 1 |
| Hoffmann, W | 2 |
| Lane, RM | 1 |
| Darreh-Shori, T | 1 |
| Meguro, K | 1 |
| Ouchi, Y | 1 |
| Akanuma, K | 1 |
| Meguro, M | 1 |
| Kasai, M | 1 |
| Jellinge, ME | 1 |
| Ferguson, AH | 1 |
| Naharci, MI | 1 |
| Ozturk, A | 1 |
| Yasar, H | 1 |
| Cintosun, U | 1 |
| Kocak, N | 1 |
| Bozoglu, E | 1 |
| Tasci, I | 1 |
| Doruk, H | 1 |
| Mehra, R | 1 |
| Sodhi, RK | 1 |
| Aggarwal, N | 1 |
| Bohlken, J | 1 |
| Weber, S | 1 |
| Rapp, MA | 1 |
| Kostev, K | 1 |
| Lai, EC | 1 |
| Wong, MB | 1 |
| Iwata, I | 2 |
| Zhang, Y | 2 |
| Hsieh, CY | 1 |
| Kao Yang, YH | 1 |
| Setoguchi, S | 2 |
| Huang, AR | 1 |
| Redpath, CJ | 1 |
| van Walraven, C | 1 |
| Wübbeler, M | 1 |
| Heinrich, S | 1 |
| Meyer, S | 1 |
| Schaefer-Walkmann, S | 1 |
| Wu, CY | 1 |
| Hu, HY | 1 |
| Chow, LH | 1 |
| Chou, YJ | 1 |
| Huang, N | 1 |
| Wang, PN | 1 |
| Li, CP | 1 |
| Manabe, Y | 1 |
| Ino, T | 1 |
| Yamanaka, K | 1 |
| Kosaka, K | 2 |
| Celik, IE | 1 |
| Acar, B | 1 |
| Çay, S | 1 |
| Gu, C | 1 |
| Shen, T | 1 |
| An, H | 1 |
| Yuan, C | 1 |
| Zhou, J | 1 |
| Ye, Q | 1 |
| Liu, T | 1 |
| Wang, X | 1 |
| Zhang, T | 1 |
| Ikeda, M | 1 |
| Mori, E | 2 |
| Iseki, E | 1 |
| Katayama, S | 1 |
| Higashi, Y | 1 |
| Hashimoto, M | 1 |
| Miyagishi, H | 1 |
| Nakagawa, M | 1 |
| Ali, TB | 1 |
| Schleret, TR | 1 |
| Reilly, BM | 1 |
| Chen, WY | 1 |
| Abagyan, R | 1 |
| Szeto, JY | 1 |
| Lewis, SJ | 1 |
| Thornton, SL | 1 |
| Pchelnikova, JL | 1 |
| Cantrell, FL | 1 |
| Soysal, P | 1 |
| Isik, AT | 1 |
| Tomasović, S | 1 |
| Sremec, J | 1 |
| Košćak, J | 1 |
| Klepac, N | 1 |
| Draganić, P | 1 |
| Bielen, I | 1 |
| Miranda, LF | 1 |
| Gomes, KB | 1 |
| Tito, PA | 1 |
| Silveira, JN | 1 |
| Pianetti, GA | 1 |
| Byrro, RM | 1 |
| Peles, PR | 1 |
| Pereira, FH | 1 |
| Santos, TR | 1 |
| Assini, AG | 1 |
| Ribeiro, VV | 1 |
| Moraes, EN | 1 |
| Caramelli, P | 1 |
| Perez-Lloret, S | 1 |
| Peralta, MC | 1 |
| Barrantes, FJ | 1 |
| Yabuki, Y | 1 |
| Matsuo, K | 1 |
| Hirano, K | 1 |
| Shinoda, Y | 1 |
| Moriguchi, S | 1 |
| Fukunaga, K | 1 |
| Caramillo, EM | 1 |
| Echevarria, DJ | 1 |
| Pariente, A | 1 |
| Helmer, C | 1 |
| Merliere, Y | 1 |
| Moore, N | 1 |
| Fourrier-Réglat, A | 1 |
| Dartigues, JF | 1 |
| Imamura, K | 1 |
| Wada-Isoe, K | 1 |
| Kowa, H | 1 |
| Tanabe, Y | 1 |
| Nakashima, K | 1 |
| van Straaten, EC | 1 |
| Harvey, D | 2 |
| Scheltens, P | 2 |
| Barkhof, F | 1 |
| Petersen, RC | 2 |
| Thal, LJ | 2 |
| Jack, CR | 2 |
| DeCarli, C | 2 |
| Laks, J | 1 |
| Engelhardt, E | 1 |
| Massoud, F | 1 |
| Dorais, M | 1 |
| Charbonneau, C | 1 |
| Lescrauwaet, B | 1 |
| Boucher, JM | 1 |
| LeLorier, J | 1 |
| Irizarry, MC | 1 |
| Raman, R | 2 |
| Schwarzschild, MA | 1 |
| Becerra, LM | 1 |
| Thomas, RG | 1 |
| Peterson, RC | 1 |
| Ascherio, A | 1 |
| Aisen, PS | 1 |
| Ishida, T | 2 |
| Kamei, C | 2 |
| Binder, C | 1 |
| Dalziel, W | 1 |
| Smyth, S | 1 |
| Camacho, F | 1 |
| Shega, JW | 1 |
| Ellner, L | 1 |
| Lau, DT | 1 |
| Maxwell, TL | 1 |
| Sakakibara, R | 1 |
| Ogata, T | 1 |
| Uchiyama, T | 1 |
| Kishi, M | 1 |
| Ogawa, E | 1 |
| Isaka, S | 1 |
| Yuasa, J | 1 |
| Yamamoto, T | 1 |
| Ito, T | 1 |
| Yamanishi, T | 1 |
| Awa, Y | 1 |
| Yamaguchi, C | 1 |
| Takahashi, O | 1 |
| Agrawal, R | 3 |
| Tyagi, E | 2 |
| Shukla, R | 3 |
| Nath, C | 4 |
| Parlayan, E | 1 |
| Yulug, B | 1 |
| Bakar, M | 1 |
| Gumustas, O | 1 |
| Hernandez, RK | 1 |
| Farwell, W | 1 |
| Cantor, MD | 1 |
| Lawler, EV | 1 |
| Obering, C | 2 |
| Batrash, A | 1 |
| Suga, A | 1 |
| Akagi, M | 1 |
| Kamat, PK | 1 |
| Tota, S | 1 |
| Saxena, G | 2 |
| Katona, C | 1 |
| Kinoshita, T | 1 |
| Hanabusa, H | 1 |
| Mollenhauer, B | 1 |
| Förstl, H | 1 |
| Deuschl, G | 1 |
| Storch, A | 1 |
| Oertel, W | 1 |
| Trenkwalder, C | 1 |
| Scharre, DW | 1 |
| Vekeman, F | 1 |
| Lefebvre, P | 1 |
| Mody-Patel, N | 1 |
| Kahler, KH | 1 |
| Duh, MS | 1 |
| Rosenbloom, MH | 1 |
| Brown, J | 1 |
| Berlowitz, DR | 1 |
| Budson, AE | 1 |
| Landau, R | 1 |
| Kremer, J | 1 |
| Seitz, DP | 1 |
| Gill, SS | 2 |
| Gruneir, A | 1 |
| Austin, PC | 1 |
| Anderson, G | 1 |
| Reimer, CL | 1 |
| Rochon, PA | 2 |
| Iliffe, S | 1 |
| McGrath, T | 1 |
| Mitchell, D | 1 |
| Lo, D | 1 |
| Grossberg, GT | 1 |
| Doody, RS | 2 |
| Cummings, JL | 5 |
| Farlow, MR | 1 |
| Koeber, R | 1 |
| Kluenemann, HH | 1 |
| Waimer, R | 1 |
| Koestlbacher, A | 1 |
| Wittmann, M | 1 |
| Brandl, R | 1 |
| Doerfelt, A | 1 |
| Jahner, T | 1 |
| Melchner, D | 1 |
| Haen, E | 1 |
| Atri, A | 2 |
| Bidzan, L | 1 |
| Bidzan, M | 1 |
| Leelavathi, M | 1 |
| Rosdinom, R | 1 |
| Suguna, M | 1 |
| Nanaumi, Y | 1 |
| Matoba, S | 1 |
| Onda, M | 1 |
| Tanaka, R | 1 |
| Tsubota, K | 1 |
| Mukai, Y | 1 |
| Sakurai, H | 1 |
| Hayase, Y | 1 |
| Arakawa, Y | 1 |
| Rolinski, M | 1 |
| Fox, C | 1 |
| Maidment, I | 1 |
| McShane, R | 1 |
| Ihl, R | 2 |
| Toba, K | 1 |
| Kimura, S | 1 |
| Yamada, Y | 1 |
| Machida, A | 1 |
| Kozaki, K | 1 |
| Hiraoka, K | 1 |
| Okamura, N | 1 |
| Funaki, Y | 1 |
| Hayashi, A | 1 |
| Tashiro, M | 1 |
| Hisanaga, K | 1 |
| Fujii, T | 1 |
| Takeda, A | 1 |
| Yanai, K | 1 |
| Iwata, R | 1 |
| Dubois, B | 1 |
| Tolosa, E | 1 |
| Katzenschlager, R | 1 |
| Emre, M | 1 |
| Lees, AJ | 1 |
| Schumann, G | 1 |
| Pourcher, E | 1 |
| Gray, J | 1 |
| Thomas, G | 1 |
| Swartz, J | 1 |
| Hsu, T | 1 |
| Moline, ML | 1 |
| Rountree, SD | 1 |
| Lopez, OL | 2 |
| Fosbøl, EL | 1 |
| Peterson, ED | 1 |
| Holm, E | 1 |
| Gislason, GH | 1 |
| Curtis, LH | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Oh, YS | 1 |
| Kim, JS | 1 |
| Ryu, DW | 1 |
| Lee, KS | 1 |
| Rösler, M | 1 |
| Inglis, F | 1 |
| Steinman, MA | 1 |
| Covinsky, KE | 1 |
| Finucane, TE | 2 |
| Cipriani, G | 1 |
| Bianchetti, A | 1 |
| Trabucchi, M | 1 |
| Hartmann, S | 1 |
| Möbius, HJ | 1 |
| McLaren, AT | 1 |
| Allen, J | 1 |
| Murray, A | 1 |
| Ballard, CG | 1 |
| Kenny, RA | 1 |
| Singh, S | 1 |
| Dudley, C | 1 |
| Werber, EA | 1 |
| Gandelman-Marton, R | 1 |
| Klein, C | 1 |
| Rabey, JM | 2 |
| Prasher, VP | 1 |
| Adams, C | 1 |
| Holder, R | 1 |
| Honig, LS | 1 |
| Bell, K | 1 |
| Chin, SS | 1 |
| Margallo-Lana, ML | 1 |
| Ballard, C | 1 |
| Morris, C | 1 |
| Kay, D | 1 |
| Tyrer, S | 1 |
| Moore, B | 1 |
| Fuchsberger, T | 1 |
| Möller, HJ | 1 |
| Hampel, H | 1 |
| Minett, TS | 1 |
| Thomas, A | 1 |
| Wilkinson, LM | 1 |
| Daniel, SL | 1 |
| Sanders, J | 3 |
| Richardson, J | 2 |
| Littlewood, E | 2 |
| Myint, P | 1 |
| Newby, J | 3 |
| McKeith, IG | 3 |
| Terao, T | 1 |
| Shimomura, T | 1 |
| Nakamura, J | 1 |
| Urakami, K | 1 |
| Leroi, I | 1 |
| Brandt, J | 2 |
| Reich, SG | 1 |
| Lyketsos, CG | 2 |
| Grill, S | 1 |
| Thompson, R | 1 |
| Marsh, L | 1 |
| Hori, K | 1 |
| Tominaga, I | 1 |
| Asaoka, T | 1 |
| Oda, T | 1 |
| Inada, T | 1 |
| Weiner, DM | 1 |
| Goodman, MW | 1 |
| Colpitts, TM | 1 |
| Feddock, MA | 1 |
| Duggento, KL | 1 |
| Nash, NR | 1 |
| Levey, AI | 1 |
| Brann, MR | 1 |
| Requena, C | 1 |
| López Ibor, MI | 1 |
| Maestú, F | 1 |
| Campo, P | 1 |
| López Ibor, JJ | 1 |
| Ortiz, T | 1 |
| Kishnani, PS | 2 |
| Sullivan, JA | 2 |
| Spiridigliozzi, GA | 2 |
| Heller, JH | 1 |
| Crissman, BG | 1 |
| Siegler, EL | 1 |
| Reidenberg, M | 1 |
| Lampl, Y | 1 |
| Sadeh, M | 1 |
| Lorberboym, M | 1 |
| Bronskill, SE | 1 |
| Mamdani, M | 1 |
| Sykora, K | 1 |
| Li, P | 1 |
| Shulman, KI | 1 |
| Anderson, GM | 1 |
| Hillmer, MP | 1 |
| Wodchis, WP | 1 |
| Jagust, W | 1 |
| Warner, J | 3 |
| Butler, R | 3 |
| Arya, P | 2 |
| Birks, J | 1 |
| Kondoh, T | 1 |
| Amamoto, N | 1 |
| Doi, T | 1 |
| Hamada, H | 1 |
| Ogawa, Y | 1 |
| Nakashima, M | 1 |
| Aikawa, K | 1 |
| Aoki, M | 1 |
| Harada, J | 1 |
| Moriuchi, H | 1 |
| Thomas, DA | 1 |
| Libon, DJ | 1 |
| Ledakis, GE | 1 |
| Geldmacher, DS | 1 |
| Ellis, JM | 1 |
| Ravina, B | 2 |
| Putt, M | 1 |
| Siderowf, A | 1 |
| Farrar, JT | 1 |
| Gillespie, M | 1 |
| Crawley, A | 1 |
| Fernandez, HH | 1 |
| Trieschmann, MM | 1 |
| Reichwein, S | 1 |
| Simuni, T | 1 |
| Gasper, MC | 1 |
| Ott, BR | 1 |
| Lapane, KL | 1 |
| Logan, A | 1 |
| Lu, S | 1 |
| Hill, J | 1 |
| Fillit, H | 1 |
| Riepe, MW | 1 |
| Thomas, AJ | 1 |
| Burn, DJ | 1 |
| Rowan, EN | 1 |
| Cousins, D | 1 |
| Pakrasi, S | 1 |
| Benke, T | 1 |
| Köylü, B | 1 |
| Delazer, M | 1 |
| Trinka, E | 1 |
| Kemmler, G | 1 |
| Olsen, CE | 1 |
| Poulsen, HD | 1 |
| Lublin, HK | 1 |
| Schill, D | 1 |
| Oude Voshaar, RC | 1 |
| Burns, A | 1 |
| Olde Rikkert, MG | 1 |
| Yener, GG | 1 |
| Kaya, GC | 1 |
| Oztürk, V | 1 |
| Akdal, G | 1 |
| Chong, MS | 1 |
| Vinters, HV | 1 |
| Gustavson, AR | 1 |
| Kouta, Y | 1 |
| Sakurai, T | 1 |
| Yokono, K | 1 |
| Mazeh, D | 1 |
| Zemishlani, H | 1 |
| Barak, Y | 1 |
| Mirecki, I | 1 |
| Paleacu, D | 1 |
| Wuntakal, B | 1 |
| Bourgeois, JA | 1 |
| Farzin, F | 1 |
| Brunberg, JA | 1 |
| Tassone, F | 1 |
| Hagerman, P | 1 |
| Zhang, L | 1 |
| Hessl, D | 1 |
| Hagerman, R | 1 |
| Ringman, JM | 1 |
| Ceravolo, R | 1 |
| Volterrani, D | 1 |
| Frosini, D | 1 |
| Bernardini, S | 1 |
| Rossi, C | 1 |
| Logi, C | 1 |
| Manca, G | 1 |
| Kiferle, L | 1 |
| Mariani, G | 1 |
| Murri, L | 1 |
| Bonuccelli, U | 1 |
| McRae, T | 1 |
| Zhang, R | 1 |
| Mazza, M | 1 |
| Capuano, A | 1 |
| Bria, P | 1 |
| Mazza, S | 1 |
| Okazaki, T | 1 |
| Furukawa, K | 1 |
| Kubo, H | 1 |
| Tsutsui, M | 1 |
| Furukawa, E | 1 |
| Asada, M | 1 |
| Yamaya, M | 1 |
| Seki, T | 1 |
| Iwaski, K | 1 |
| Arai, H | 1 |
| Rowan, E | 1 |
| Saxby, BK | 1 |
| O'Brien, JT | 1 |
| Burn, D | 1 |
| Mosimann, U | 1 |
| Daniel, S | 1 |
| Wesnes, K | 1 |
| Mendez, MF | 1 |
| Shapira, JS | 1 |
| McMurtray, A | 1 |
| Licht, E | 1 |
| Frisoni, GB | 1 |
| Clark, CM | 1 |
| Grundman, M | 1 |
| Jin, S | 1 |
| Müller, T | 1 |
| Welnic, J | 1 |
| Fuchs, G | 1 |
| Baas, H | 1 |
| Ebersbach, G | 1 |
| Reichmann, H | 1 |
| Kurlan, R | 1 |
| Cummings, J | 1 |
| Thal, L | 1 |
| Rosenblatt, A | 1 |
| Samus, QM | 1 |
| Onyike, CU | 1 |
| Baker, AS | 1 |
| McNabney, M | 1 |
| Mayer, LS | 1 |
| Albert, MS | 1 |
| Blacker, D | 1 |
| Corrao, S | 1 |
| Scaglione, R | 1 |
| Calvo, L | 1 |
| Licata, G | 1 |
| Korczyn, AD | 1 |
| Anghelescu, I | 1 |
| Heuser, I | 1 |
| Leitch, A | 1 |
| McGinness, P | 1 |
| Wallbridge, D | 1 |
| Jakovljevic, M | 1 |
| Vuksan-Cusa, B | 1 |
| Topic, R | 1 |
| Rueda, N | 1 |
| Flórez, J | 1 |
| Martínez-Cué, C | 1 |
| Singh, SP | 1 |
| Landmark, K | 1 |
| Reikvam, A | 1 |
| Qaseem, A | 1 |
| Snow, V | 1 |
| Cross, JT | 1 |
| Forciea, MA | 1 |
| Hopkins, R | 1 |
| Shekelle, P | 1 |
| Adelman, A | 1 |
| Mehr, D | 1 |
| Schellhase, K | 1 |
| Campos-Outcalt, D | 1 |
| Santaguida, P | 2 |
| Owens, DK | 1 |
| Raina, P | 1 |
| Ismaila, A | 1 |
| Patterson, C | 1 |
| Cowan, D | 1 |
| Levine, M | 1 |
| Booker, L | 1 |
| Oremus, M | 1 |
| Sharma, B | 1 |
| Singh, N | 1 |
| Singh, M | 1 |
| Jaggi, AS | 1 |
| Morrison, LJ | 1 |
| Liao, S | 1 |
| Graham, L | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Nichols, ME | 1 |
| Greenhalgh, T | 1 |
| Boothby, H | 1 |
| Zaidi, SM | 1 |
| Seth, V | 1 |
| Khalaf, S | 1 |
| Jameel, H | 1 |
| Mahomed, S | 1 |
| Geizer, M | 1 |
| Ancill, RJ | 1 |
| Post, SG | 1 |
| Whitehouse, PJ | 1 |
| Schneider, LS | 1 |
| Shea, C | 1 |
| MacKnight, C | 1 |
| Kaufer, DI | 1 |
| Catt, KE | 1 |
| DeKosky, ST | 1 |
| Benazzi, F | 1 |
| Wengel, SP | 2 |
| Roccaforte, WH | 2 |
| Burke, WJ | 2 |
| Aarsland, D | 1 |
| Brønnick, K | 1 |
| Karlsen, K | 1 |
| Walter, BK | 1 |
| Doraiswamy, PM | 1 |
| Krishnan, KR | 1 |
| Tapsfield, WG | 1 |
| Jelly, DM | 1 |
| Matthews, H | 1 |
| Wilkinson, D | 1 |
| Holmes, D | 1 |
| Tiseo, P | 1 |
| Pryse-Phillips, W | 1 |
| Charlesworth, G | 1 |
| Shepstone, L | 1 |
| McGirr, G | 1 |
| Compton, SA | 1 |
| Devi, G | 1 |
| Silver, J | 1 |
| Spiessl, H | 1 |
| Marienhagen, J | 1 |
| Stöhr, H | 1 |
| Klein, HE | 1 |
| Pollock, BG | 1 |
| Mulsant, BH | 1 |
| Rosen, J | 1 |
| Sweet, RA | 1 |
| Mazumdar, S | 1 |
| Bharucha, A | 1 |
| Marin, R | 1 |
| Jacob, NJ | 1 |
| Huber, KA | 1 |
| Kastango, KB | 1 |
| Chew, ML | 1 |
| Stryjer, R | 1 |
| Bar, F | 1 |
| Strous, RD | 1 |
| Baruch, Y | 1 |
| Putt, ME | 1 |
| Roe, CM | 1 |
| Anderson, MJ | 1 |
| Spivack, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dementia Clinical Trials: A Study on the Clinical Trial Participation of Dementia Patients[NCT05850000] | 500 participants (Anticipated) | Observational | 2024-05-31 | Not yet recruiting | |||
| Dementia: Life- and Personcentered Help in Germany[NCT01401582] | 634 participants (Actual) | Interventional | 2012-01-31 | Active, not recruiting | |||
| A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846] | Phase 2/Phase 3 | 12 participants (Anticipated) | Interventional | 2023-07-31 | Recruiting | ||
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia[NCT02415062] | Phase 2 | 150 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease[NCT02521558] | 30 participants (Actual) | Interventional | 2015-09-30 | Terminated (stopped due to Enrollment was halted early because of low adherence to the intervention.) | |||
| Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study[NCT02420756] | 18,488 participants (Actual) | Observational [Patient Registry] | 2016-02-29 | Completed | |||
| A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia[NCT00545974] | Phase 4 | 81 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)[NCT00000173] | Phase 3 | 0 participants | Interventional | 1999-03-31 | Completed | ||
| A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)[NCT01429623] | Phase 2 | 210 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study[NCT04249869] | Phase 1/Phase 2 | 28 participants (Anticipated) | Interventional | 2020-02-01 | Not yet recruiting | ||
| Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial[NCT02781220] | 69 participants (Actual) | Observational | 2016-07-31 | Active, not recruiting | |||
| Implications for Management of PET Amyloid Classification Technology[NCT02778971] | 41 participants (Actual) | Observational | 2016-06-30 | Completed | |||
| An Open Label 24-Week, Flexible Dose Trial to Assess the Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies[NCT00230997] | Phase 3 | 50 participants | Interventional | 2002-12-31 | Completed | ||
| Continuation Pharmacotherapy for Agitation of Dementia[NCT00073658] | Phase 2 | 137 participants | Interventional | 2000-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neuropsychiatric Inventory (NPI; Cummings 1997); The NPI represents an interview by proxy on twelve dimensions of neuropsychiatric behaviors, i.e. delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The presence (0= no, 1= yes) is asked. If present, the severity (rated 1 through 3; mild to severe) and frequency (1 to 4, rarely to very often) of each neuropsychiatric symptom are rated on. Thus the score for each dimension ranges from 0 = not present, 1= mildly and rarely to 12 = severe and often. A total NPI score is calculated as the sum of the frequency by severity scores ofeach domain range: 0 to 144, the higher the more neuropsychiatric symptomatic). (NCT01401582)
Timeframe: one year after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Care as Usual | 15.2 |
| Implementation of Dementia Care Manager | 8.2 |
"Caregiver burden was assessed using the Berliner Inventar zur Angehörigenbelastung - Demenz (BIZA-D) (Zank et al., 2006). The BIZAD was developed to assess objective as well as subjective burden due to caring for a person wit dementia (PWD). It consists of 88 items covering 20 dimensions of caregiver burden. Objective burden is divided into six dimensions: 1) basic care tasks like support eating, hygiene etc (7 items), 2) extended care tasks like supporting grocery shopping, legal affairs etc. (3 items), 3) Motivation and Guidance (4 items), 4) emotional support (4 items), 5) supporting maintenance of social contacts (3 items) and 6) supervision (4 items). Each item has to be rated regarding the frequency of the support needed on a 5-Point scale (example: supervision; Does the patient need this kind of support: 1=always, 2= mostly, 3=partly, 4=hardly, 5= not at all). Then each item asks: Who is providing this support: all by someone else, mostly by someone else, evenly distributed" (NCT01401582)
Timeframe: one year after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Care as Usual | 0.4 |
| Implementation of Dementia Care Manager | 0.13 |
medication was systematically reviewed; A computer-based home medication review (HMR) encompasses all medications used by the study participants and includes questions about compliance, adverse effects and drug administration. The collection of primary data on medication in the context of the HMR includes both prescription drugs and over-the-counter drugs. The assignment was then integrated using a master file of the Pharmaceutical Index. The following antidementia drugs were considered: donepezil (N06AD02), rivastigmine (N06AD03), galantamine (N06AD04) and memantine (N06AX01). (NCT01401582)
Timeframe: one year after baseline assessment
| Intervention | participants (Number) |
|---|---|
| Care as Usual | 31 |
| Implementation of Dementia Care Manager | 114 |
The Quality of Life in Alzheimer's Disease (Qol-AD; Logsdon et al. 2002) was used. This measure designed specifically to obtain a rating of the patient's quality of life from both the patient and the caregiver. Each item is rated on a four point scale, with 1 being poor and 4 being excellent. Total scores, obtained by the sum of all 13 items, range from 13 to 52. (NCT01401582)
Timeframe: one year after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Care as Usual | 2.8 |
| Implementation of Dementia Care Manager | 2.8 |
"The functional status was assessed using the Bayer Activities of Daily Living Scale (B-ADL). It coonsits of 25 Items indicating everyday problems/ challenges. Their occurence is rated on a scale of 1 never, to 10 always. All ratings are added and divided by the number of items. This yields a mean score of 1 to 10, where 1 indicates the lowest possible impairment and 10 indicates the highest possible impairment." (NCT01401582)
Timeframe: one year after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Care as Usual | 4.4 |
| Implementation of Dementia Care Manager | 4.9 |
"Having to deal with multimorbidity and polypharmacy in a sample of chronically ill elderly, we also analyze potentially inappropriate medication (PIM), defined as a drug for which the risk of an adverse event outweighs the clinical benefit, particularly when there is evidence in favor of a safer or more effective alternative therapy for the same condition. The PIM were identified using the Priscus list, which contains 83 drugs from 18 different drug classes." (NCT01401582)
Timeframe: one year after baseline assessment
| Intervention | Participants (Count of Participants) |
|---|---|
| Care as Usual | 19 |
| Implementation of Dementia Care Manager | 77 |
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions indicate that the patient has problems with a particular sub-domain of behavior, the caregiver is only then asked all the questions about that domain, rating the frequency of the symptoms on a 4-point scale, their severity on a 3-point scale, and the distress the symptom causes them on a 5-point scale. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement. (NCT00545974)
Timeframe: Baseline, 26 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | -1.9 |
| Placebo | 0.3 |
The scale is rated on a 7-point scale, using a range of responses from 1 (very much improved) through 7 (very much worse). The clinician compares the participant's current condition to the condition at admission to the project. (NCT00545974)
Timeframe: 26 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Memantine | 4.4 |
| Placebo | 4.8 |
(NCT00545974)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Memantine | 1 |
| Placebo | 2 |
"Clinical dementia rating sum of boxes CDR-SB (0-18) high scores indicate high impairment.~Functional activities questionnaire FAQ (0-30) high scores indicate high impairment.~Texas functional living scale TFLS (0 to 52) high scores suggest better instrumental activities of daily living functioning.~Mini-Mental State Examination MMSE (0-30) low scores indicate low cognition. The executive interview EXIT25 (0 to 50) high scores indicate more executive impairment.~A modified unified Parkinson's disease rating scale UPDRS (0-199) high scores indicate worse disability.~Boston naming test (0-15) low scores indicate more retrieval difficulties." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| CDR-SB | FAQ | TFLS | MMSE | EXIT25 | UPDRS | Boston naming test | |
| Memantine | 1.5 | 4.3 | -3.7 | -1.2 | 1.9 | 1.7 | -1.4 |
| Placebo | 1.5 | 2.9 | -2.8 | -0.9 | 0.7 | 1.4 | 0.7 |
"Letter fluency, score is number of words recalled starting with a specified letter for 60 seconds. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials for the score. Low scores indicate high impairment~Category fluency, score is number of items generated belonging to a specific category (such as animals) in 60 seconds, low scores indicate high impairment.~Digit symbol, score is number of symbols that correctly corresponded to the random numerals entered in the form in 90 seconds. Participants are given a table of numerals with matching symbols, and a form with random numerals with open spaces. Low scores indicate high impairment.~Digits backwards, score is number of digits backwards recalled (range: 0-14), The participant hears a list of digits and is asked to repeat the digits backwards. Low scores indicate high impairment." (NCT00545974)
Timeframe: Baseline and 26 Weeks
| Intervention | number of items recalled (Mean) | |||
|---|---|---|---|---|
| Letter fluency | Category fluency | Digit symbol | Digits backwards | |
| Memantine | -0.1 | -0.5 | -3.9 | 0.1 |
| Placebo | -0.3 | -0.7 | 4.2 | -0.2 |
Mean value change (from baseline) in Disability Assessment in Dementia (DAD) across entire study period. DAD evaluates the basic and instrumental activities in daily activities of elderly people with dementia. Higher scores reflect better functioning. DAD ranges from 0 to 100. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | -0.77 |
| Placebo Control | -0.40 |
"Mean value change (from baseline) in Geriatric Depression Scale (GDS) across entire study period. The GDS ranges from 0 to 30. Scores of 0-9 are considered normal, 10-19 mildly depressed, and 20-30 severely depressed." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .084 |
| Placebo Control | .242 |
Mean value change (from baseline) in Neuropsychiatric Test Battery (NTB) across entire study period. The NTB included the following well known cognitive tests: Rey Auditory Verbal Learning Test (RAVLT), Controlled Word Association Test (COWAT), Category Fluency Test (CFT), WMS-R Digit Span, and Trail Making Part A and B. The mean value was comprised of the z score of each of these tests with all z scores in the direction of higher scores better functioning. Range -3 to +3. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .21 |
| Placebo Control | .17 |
"Total number of conversions from Mild Cognitive Impairment to Alzheimer's disease across entire 3 year study period. Conversion is determined, or defined, by a Clinical Dementia Rating (CDR) score of greater than or equal to one.~Composite rating ranges from 0 no symptoms of dementia to 3 Severe symptoms of dementia." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ladostigil Hemitartrate | 14 |
| Placebo Control | 21 |
53 reviews available for donepezil and Amentia
| Article | Year |
|---|---|
Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis.
Topics: Aripiprazole; Dementia; Donepezil; Humans; Memantine; Network Meta-Analysis; Risperidone; United Sta | 2022 |
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Human | 2021 |
Pharmacological Approaches to the Treatment of Dementia in Down Syndrome: A Systematic Review of Randomized Clinical Studies.
Topics: Acetylcholinesterase; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Humans; Memanti | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.
Topics: Adult; Brain Neoplasms; Cognition; Cognitive Dysfunction; Cranial Irradiation; Dementia; Donepezil; | 2022 |
[The use of donepezil in gait disorders in eldery patients with dementia].
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Gait; Gait Disorders, Neurologic; Humans; Inda | 2019 |
Donepezil for dementia due to Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Female; | 2020 |
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.
Topics: Alzheimer Disease; Animals; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Dementia; Donepezil; Ga | 2020 |
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interac | 2017 |
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Cognitive Dysfunction; Combined Modality Therapy; Compl | 2018 |
Charles bonnet syndrome: treating nonpsychiatric hallucinations.
Topics: Aged, 80 and over; Cognition; Dementia; Donepezil; Female; Hallucinations; Humans; Indans; Nootropic | 2013 |
"Shall I compare thee to a dose of donepezil?": cultural arts interventions in dementia care research.
Topics: Art Therapy; Dementia; Donepezil; Humans; Indans; Piperidines | 2014 |
Atypical aging in Down syndrome.
Topics: Adult; Aging; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Dementia; Donepez | 2013 |
[Cholinesterase inhibitors in the treatment of mixed dementia].
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Piperidines; Treatment Outcome | 2013 |
Drugs for cognitive loss and dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cogniti | 2013 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfuncti | 2014 |
Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value.
Topics: Acetylcholine; Acetylcholinesterase; Amyloid beta-Peptides; Apolipoproteins E; Butyrylcholinesterase | 2015 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Th | 2016 |
Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.
Topics: Animals; Cholinergic Agents; Cholinergic Neurons; Clinical Trials as Topic; Cognition Disorders; Dem | 2016 |
Alzheimer's disease in the zebrafish: where can we take it?
Topics: Alzheimer Disease; Animals; Dementia; Disease Models, Animal; Donepezil; Humans; Indans; Memantine; | 2017 |
Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy; Evidence-Base | 2008 |
Issues facing home-based medical support services.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Caregivers; Delirium; Dementia; Diagnosis, Differenti | 2010 |
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.
Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; | 2010 |
[Cholinesterase inhibitors for treating dementia. Review].
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piper | 2010 |
Use of memantine for the treatment of dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Humans; Indans; | 2011 |
Reviewing the role of donepezil in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Nootropic Agents; | 2012 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; G | 2011 |
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Lewy Body Disea | 2012 |
Gingko biloba extract EGb 761®: clinical data in dementia.
Topics: Activities of Daily Living; Cognition; Dementia; Donepezil; Drug Therapy, Combination; Ginkgo biloba | 2012 |
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Evidence-B | 2013 |
The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Topics: Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans | 2002 |
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Topics: Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Nootropic A | 2002 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Cli | 2003 |
[Limbic neurofibrillary tangle dementia].
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Diagnosis, Differential; Donepezil; Fe | 2004 |
Representation of patients with dementia in clinical trials of donepezil.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; | 2004 |
Dementia: finding the signals in the noise.
Topics: Alzheimer Disease; Dementia; Donepezil; Estrogen Replacement Therapy; Humans; Indans; Magnetic Reson | 2005 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamin | 2004 |
Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
Topics: Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorder | 2004 |
Cholinesterase inhibitors in the treatment of dementia.
Topics: Acetylcholine; Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost of Ill | 2005 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootr | 2004 |
Cholinergic treatment: what are the early neuropathological targets?
Topics: Aged; Alzheimer Disease; Brain; Cholinergic Agents; Cholinesterase Inhibitors; Dementia; Donepezil; | 2005 |
Drug therapy of dementia in elderly patients. A review.
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotectiv | 2005 |
[Cognitive dysfunction and dementia associated with elderly diabetes].
Topics: Aged; Antihypertensive Agents; Brain; Cognition Disorders; Dementia; Diabetes Mellitus, Type 2; Done | 2006 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; | 2005 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Human | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
Mild cognitive impairment and dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Dementi | 2006 |
[Acetylcholinesterase inhibitors for dementia--an update].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galanta | 2007 |
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Donepezil; Evidence-Base | 2008 |
Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excit | 2008 |
Dementia in the elderly.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Female; | 1997 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; D | 1998 |
Rational design of anti-dementia therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Drug De | 1999 |
Do we have drugs for dementia? No.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Ginkgo biloba; Humans; Indans; Ne | 1999 |
Approaches to memory loss in neuropsychiatric disorders.
Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinesterase Inhibitors; Dementia; D | 2000 |
28 trials available for donepezil and Amentia
| Article | Year |
|---|---|
Cognitive change in donepezil treated patients with vascular or mixed dementia.
Topics: Aged; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Female; Humans; Indans; Male; Middl | 2013 |
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia | 2014 |
Antidementia drug treatment in people screened positive for dementia in primary care.
Topics: Aged; Aged, 80 and over; Dementia; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; | 2015 |
[Nourishing Xin and Shen method improved mild cognitive impairment due to subcortical small vessel disease: a clinical study].
Topics: Alzheimer Disease; Biomedical Research; Cognition; Cognitive Dysfunction; Dementia; Donepezil; Drugs | 2015 |
Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Dementia; Donepezil; Double-Blind Method; Drug Therap | 2015 |
Adequacy of Using Consensus Guidelines for Diagnosis of Dementia with Lewy Bodies in Clinical Trials for Drug Development.
Topics: Aged; Aged, 80 and over; Consensus; Dementia; Donepezil; Female; Guideline Adherence; Humans; Indans | 2016 |
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Atrophy; Brain; Cerebral Ventricl | 2008 |
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Cholinesterase Inhibitors; Dementia; Donepezil | 2012 |
Cardiovascular effects of donepezil in patients with dementia.
Topics: Aged; Autonomic Nervous System; Cardiovascular System; Cholinesterase Inhibitors; Dementia; Donepezi | 2003 |
The clinical use of P300 event related potentials for the evaluation of cholinesterase inhibitors treatment in demented patients.
Topics: Acetylcholine; Aged; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; De | 2003 |
Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Humans; Indans; Lo | 2003 |
What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Drug Administration Schedule; Humans; Indans; Lewy B | 2003 |
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Double-Blind Method; Female | 2004 |
Effects of cholinergic drugs and cognitive training on dementia.
Topics: Aged; Aging; Alzheimer Disease; Cholinergic Agents; Cognition; Cognitive Behavioral Therapy; Combine | 2004 |
Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cross-Over Studies; Dementia; Donepezil; Double- | 2005 |
Cholinergic treatment of amnesia following basal forebrain lesion due to aneurysm rupture--an open-label pilot study.
Topics: Adult; Amnesia; Aneurysm, Ruptured; Case-Control Studies; Cholinesterase Inhibitors; Dementia; Donep | 2005 |
Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Comorbidity; Cr | 2006 |
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.
Topics: Aged; Antiparkinson Agents; Brain; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; I | 2006 |
Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Demography; Donepezil; Double-Blind Method; Factor Analys | 2006 |
Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Dementi | 2006 |
Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Attention; Chi-Square Distribution; Cholinesterase Inhibitors; Cognition; D | 2007 |
Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia.
Topics: Behavioral Symptoms; Cholinesterase Inhibitors; Compulsive Behavior; Dementia; Donepezil; Female; Hu | 2007 |
Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia.
Topics: Behavioral Symptoms; Cholinesterase Inhibitors; Compulsive Behavior; Dementia; Donepezil; Female; Hu | 2007 |
Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia.
Topics: Behavioral Symptoms; Cholinesterase Inhibitors; Compulsive Behavior; Dementia; Donepezil; Female; Hu | 2007 |
Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia.
Topics: Behavioral Symptoms; Cholinesterase Inhibitors; Compulsive Behavior; Dementia; Donepezil; Female; Hu | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil.
Topics: Aged; Analysis of Variance; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Indans; | 2006 |
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Antips | 2007 |
Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Dementia; Donepezil; Female; Geriatric Assessme | 1998 |
Cholinergic therapy for Down's syndrome.
Topics: Adaptation, Psychological; Adult; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Dru | 1999 |
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavioral Symptoms; Citalopram; Dementia; Donepezil; | 2002 |
131 other studies available for donepezil and Amentia
| Article | Year |
|---|---|
A Nationwide Multi-Center Questionnaire Survey on the Real-World State and Clinical Management of Poststroke Dementia in Japan.
Topics: Aged; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Donepezil; Female; Galantamine; Huma | 2021 |
Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Galantamine; Humans; Male; Medicare; M | 2022 |
Patterns of dementia treatment in older adults with Parkinson's disease using nationwide medical claims data.
Topics: Aged; Cholinergic Antagonists; Cholinesterase Inhibitors; Cohort Studies; Dementia; Donepezil; Femal | 2022 |
Effectiveness of an integrative medicine approach to improve cognitive dysfunction and dementia: An observational study.
Topics: Anticonvulsants; Cognition; Cognitive Dysfunction; Dementia; Donepezil; Humans; Integrative Medicine | 2022 |
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium.
Topics: Cholinergic Agents; Critical Illness; Delirium; Dementia; Donepezil; Humans | 2023 |
Lecanemab: Looking Before We Leap.
Topics: Aged; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Dementia; Donepezil; Humans; Medicare; U | 2023 |
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine | 2020 |
Delay-dependent cholinergic modulation of visual short-term memory in rhesus macaques.
Topics: Animals; Behavior, Animal; Cholinesterase Inhibitors; Dementia; Disease Models, Animal; Donepezil; M | 2021 |
Dementia Diagnoses and Treatment in Geriatric Ward Patients: A Cross-Sectional Study in Poland.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studies; Dementia; | 2020 |
Racial Differences in Alzheimer's Disease Specialist Encounters Are Associated with Usage of Molecular Imaging and Dementia Medications: An Enterprise-Wide Analysis Using i2b2.
Topics: Academic Medical Centers; Aged; Alzheimer Disease; Black or African American; Cholinesterase Inhibit | 2021 |
Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia.
Topics: Aged; Algorithms; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Male; Nursing Home | 2021 |
Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders.
Topics: Aged; Aged, 80 and over; Asian People; Cholinergic Antagonists; Cholinesterase Inhibitors; Dementia; | 2017 |
Clinical Pearls in Geriatrics.
Topics: Acetaminophen; Aged; Aged, 80 and over; Automobile Driving; Cognition Disorders; Cognitive Dysfuncti | 2017 |
Donepezil is associated with decreased in-hospital mortality as a result of pneumonia among older patients with dementia: A retrospective cohort study.
Topics: Aged; Dementia; Donepezil; Hospital Mortality; Humans; Pneumonia; Retrospective Studies | 2018 |
Recurrent truncal dystonia (Pisa syndrome) due to donepezil - A case report.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Dystonia; Humans; Male; Middle Aged; Syndrome | 2018 |
Epidemiology of Dementia in Elderly Chronic Obstructive Pulmonary Disease Patients Living in China's Northwestern High-Elevation Area.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Aged, 80 and over; Altitude; Asian People; C | 2018 |
Anticholinergic medicines use among older adults before and after initiating dementia medicines.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Australia; Cholinergic Antagonists; Cholinesterase In | 2019 |
[Patterns of antidemential drug use in a group of patients from Colombia].
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Colombia; Cross-Sectional Studies; Dementia; Don | 2019 |
Factors Associated With Deprescribing Acetylcholinesterase Inhibitors in Older Nursing Home Residents With Severe Dementia.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Deprescriptions; Donepezil; Female; Ho | 2019 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galanta | 2013 |
[Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Child; Child, Preschool; Cholinesterase Inhib | 2013 |
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
Topics: Aged; Cholinesterase Inhibitors; Cilostazol; Dementia; Donepezil; Drug Therapy, Combination; Female; | 2014 |
Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia.
Topics: Aged; Cognition Disorders; Dementia; Donepezil; Electrocardiography; Female; Heart; Humans; Indans; | 2014 |
Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Dose-Response Re | 2014 |
Anti-dementia drugs in a psychiatric hospital for dementia patients.
Topics: Aged; Dementia; Donepezil; Galantamine; Hospitalization; Hospitals, Psychiatric; Humans; Indans; Noo | 2014 |
Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Disease Progress | 2014 |
[Severe bradycardia in general anaesthesia in a patient treated with cholinesterase inhibitors for dementia].
Topics: Aged; Anesthesia, General; Anesthetics, Intravenous; Bradycardia; Cholinesterase Inhibitors; Dementi | 2015 |
Galantamine improves sleep quality in patients with dementia.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Cholinesterase Inhibitors; Dementia; Donepezil; Do | 2015 |
Memory restorative ability of clioquinol in copper-cholesterol-induced experimental dementia in mice.
Topics: Acetylcholinesterase; Animals; Anticholesteremic Agents; Antioxidants; Behavior, Animal; Biomarkers; | 2015 |
Continuous treatment with antidementia drugs in Germany 2003-2013: a retrospective database analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Databases, Factual; Dementia; Donepezil; Female; Germany; Huma | 2015 |
Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cohort Studies; Dementia; Donepezil; Female; Gal | 2015 |
The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
Topics: Aged; Cholinesterase Inhibitors; Comorbidity; Databases, Factual; Dementia; Donepezil; Female; Galan | 2015 |
Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use.
Topics: Aged; Aged, 80 and over; Caregivers; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents | 2015 |
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan.
Topics: Cohort Studies; Dementia; Dihydroergocristine; Dihydroergotamine; Donepezil; Galantamine; Humans; In | 2015 |
Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Behavior; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition; Dement | 2016 |
An unusual cardiovascular adverse effect of donepezil.
Topics: Arrhythmias, Cardiac; Cholinesterase Inhibitors; Dementia; Donepezil; Electrocardiography; Female; H | 2015 |
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Datab | 2015 |
Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.
Topics: Child; Child, Preschool; Dementia; Donepezil; Female; Galantamine; Humans; Indans; Infant; Male; Mem | 2016 |
Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Body Mass Index; Body Weight; Cholinesterase | 2016 |
Epidemiological Characteristics of Dementia Treatment in Croatia.
Topics: Adult; Aged; Aged, 80 and over; Croatia; Databases, Factual; Dementia; Donepezil; Dopamine Agents; F | 2016 |
Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms.
Topics: Apolipoproteins E; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Cytochrome P-450 | 2017 |
Combined Memantine and Donepezil Treatment Improves Behavioral and Psychological Symptoms of Dementia-Like Behaviors in Olfactory Bulbectomized Mice.
Topics: Animals; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy, Combination; Excitatory Amino | 2017 |
Prevalence of cholinesterase inhibitors in subjects with dementia in Europe.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Europe; Galantamine; Health Policy; Humans; Indans; | 2008 |
The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia.
Topics: Aged; Cerebrovascular Circulation; Dementia; Donepezil; Gyrus Cinguli; Humans; Indans; Male; Mental | 2008 |
Drug utilization review of cholinesterase inhibitors in Quebec.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Utilization Rev | 2008 |
Plasma urate and progression of mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Boston; Cognition Disorders; Confounding Factors, Epidem | 2009 |
Characteristic effects of anti-dementia drugs on rat sleep patterns.
Topics: Animals; Dementia; Donepezil; Dose-Response Relationship, Drug; Electroencephalography; Electromyogr | 2009 |
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Delayed-A | 2009 |
Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
Topics: Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Don | 2009 |
How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist.
Topics: Aged; Aged, 80 and over; Benzilates; Chi-Square Distribution; Cholinergic Antagonists; Cholinesteras | 2009 |
A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia.
Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Biomarkers; Blood Glucose; Blotting, Wes | 2009 |
Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect.
Topics: Aged; Aspartic Acid; Brain; Cognition Disorders; Dementia; Donepezil; Female; Humans; Indans; Magnet | 2009 |
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Donepe | 2009 |
Case report: combined use of donepezil and galantamine in mixed dementia.
Topics: Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy, Combination; Galant | 2009 |
Effects of anti-dementia drugs on morphine-induced somnolence.
Topics: Animals; Dementia; Donepezil; Electroencephalography; Electromyography; Indans; Male; Memantine; Met | 2009 |
Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity.
Topics: Animals; Brain; Calcium Signaling; Cholinesterase Inhibitors; Dementia; Disease Models, Animal; Done | 2010 |
Dementia: Does depression predict donepezil response in MCI?
Topics: Cognition Disorders; Dementia; Depression; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 2009 |
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; | 2010 |
Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans | 2011 |
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Evidence is not satisfactory.
Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; | 2011 |
Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.
Topics: Aged; Aged, 80 and over; Anesthesia, General; Cholinesterase Inhibitors; Cohort Studies; Critical Ca | 2011 |
The impact of patient and public involvement in the work of the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN): case studies.
Topics: Alzheimer Disease; Biomedical Research; Community Participation; Dementia; Donepezil; Humans; Indans | 2013 |
Implementation of a cost-effective HPLC/UV-approach for medical routine quantification of donepezil in human serum.
Topics: Chromatography, High Pressure Liquid; Dementia; Donepezil; Drug Monitoring; Drug Stability; Humans; | 2012 |
Withdrawal syndrome after donepezil cessation in a patient with dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Delirium; Dementia; Donepezil; Female; Humans; Indans; | 2012 |
Pisa syndrome secondary to rivastigmine: a case report.
Topics: Aged; Benzodiazepines; Cholinesterase Inhibitors; Delusions; Dementia; Donepezil; Humans; Indans; Ma | 2012 |
[Pilot study of dementia medication compliance conducted among pharmacists providing home visits which evaluates the degree of drug compliance, as defined by numerous attributes, between patients at home and patients in a medical facility].
Topics: Activities of Daily Living; Cognition; Dementia; Donepezil; Health Facilities; House Calls; Humans; | 2012 |
[Instrumental ADL and basic ADL].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Femal | 2011 |
Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia.
Topics: Aged; Antiparasitic Agents; Brain Mapping; Case-Control Studies; Cholinergic Agents; Cholinesterase | 2012 |
Comparative cardiovascular safety of dementia medications: a cross-national study.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cohort Studies; Dementia; Denmark; Donepezil; Fe | 2012 |
Donepezil induced antecollis in a patient with Parkinson's disease dementia.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Dyskinesia, Drug-Induced; Female; Humans; Inda | 2013 |
Donepezil for nursing home patients with dementia: a reinterpretation of the evidence.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Mental Status Schedule; Nursing Home | 2003 |
Getting donepezil into the nursing home.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Mental Status Schedule; Nursing Home | 2003 |
Donepezil use in the treatment of dementia associated with Down syndrome.
Topics: Adult; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Down Syndrome; Fema | 2003 |
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Cholinesterase Inhibitors; Dementia; Donepezil; Dose-Res | 2003 |
Discontinuation syndrome following donepezil cessation.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Indans; Mid | 2003 |
Frontotemporal dementia.
Topics: Age of Onset; Dementia; Donepezil; Fatal Outcome; Frontal Lobe; Humans; Indans; Magnetic Resonance I | 2003 |
Cognitive decline in Down syndrome.
Topics: Adult; Age Factors; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Down Syndro | 2003 |
The impact of drugs against dementia on cognition in aging and mild cognitive impairment.
Topics: Adult; Aged; Aged, 80 and over; Aging; Cognition; Cognition Disorders; Dementia; Donepezil; Female; | 2003 |
Can donepezil be considered a mild antipsychotic in dementia treatment? A report of donepezil use in 6 patients.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Female; Hallucin | 2003 |
[Significance of treatment and adequate care in dementia--including point of medical comments in health care insurance system for elderly people by doctors].
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Health Services for the Aged; Humans; Indans; Insuranc | 2003 |
Functional screening of drug target genes: m1 muscarinic acetylcholine receptor phenotypes in degenerative dementias.
Topics: Aged; Cholinesterase Inhibitors; Cohort Studies; Dementia; DNA; Donepezil; Drug Delivery Systems; Fe | 2004 |
Donepezil use in Down syndrome.
Topics: Adult; Cholinesterase Inhibitors; Dementia; Donepezil; Down Syndrome; Humans; Indans; Neuropsycholog | 2004 |
Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia.
Topics: Aged; Benzhydryl Compounds; Cholinesterase Inhibitors; Cresols; Dementia; Donepezil; Drug Interactio | 2004 |
Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Indans; Male; Middle Aged; Phe | 2004 |
Does donepezil improve well-being for dementia due to Alzheimer's disease?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Piperidines; Qual | 2005 |
Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Down Syndrome; Female; H | 2005 |
Treating dementia patients with vascular lesions with donepezil: a preliminary analysis.
Topics: Aged; Alzheimer Disease; Blood Vessels; Brain; Dementia; Dementia, Vascular; Donepezil; Female; Huma | 2005 |
Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
Topics: Cholinesterase Inhibitors; Comorbidity; Cross-Over Studies; Cross-Sectional Studies; Dementia; Donep | 2005 |
Is donepezil therapy associated with reduced mortality in nursing home residents with dementia?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cohort Studies; Cross-Sectional Studies; Databases, Fact | 2005 |
When the drugs don't work.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Piperidines; Tr | 2005 |
Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Dementi | 2005 |
A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Topics: Age Factors; Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Indans; Lewy Body | 2005 |
[Dementia of trisomy 21. Improvement with donepezil].
Topics: Dementia; Donepezil; Down Syndrome; Humans; Indans; Nootropic Agents; Piperidines | 2005 |
Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; European Union; Galantamine; Humans | 2006 |
Improvement in Tc-99m HMPAO brain SPECT findings during donepezil therapy in a patient with pure akinesia.
Topics: Alexia, Pure; Brain; Cholinesterase Inhibitors; Dementia; Donepezil; Gait Disorders, Neurologic; Ind | 2005 |
Dementia with parkinsonism: what is the diagnosis?
Topics: Aged; Brain; Dementia; Diagnosis, Differential; Donepezil; Fatal Outcome; Humans; Image Processing, | 2004 |
Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine.
Topics: Aged; Antidepressive Agents, Second-Generation; Ataxia; Atrophy; Brain; Cyclohexanols; Dementia; Dom | 2006 |
Paralytic ileus after discontinuation of cholinesterase inhibitor.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Indans; Intestinal Pseudo-Obstruction; | 2006 |
Effect of anti-dementia drugs on LPS induced neuroinflammation in mice.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Brain; Cholinesterase Inhibitors; Dementia; Don | 2007 |
Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Assisted Living Facilities; Cholin | 2008 |
Methodological matters on an Alzheimer's dementia trial: is a double-blind randomized controlled study design sufficient to draw strong conclusions on treatment? Reply to Dr Mazza and colleagues.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Double-Blind Method; Ginkgo bilob | 2007 |
Comments on the article by Mazza et al. concerning Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Double-Blind Method; Ginkgo bilob | 2007 |
Calculate the QT interval in patients taking drugs for dementia.
Topics: Aged; Dementia; Donepezil; Female; Humans; Indans; Long QT Syndrome; Nootropic Agents; Piperidines; | 2007 |
Some treatment dilemmas in rapidly developing dementia: a case report.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Dementia; Depression; Diseas | 2008 |
NICE on dementia: Omitting donepezil is hardly a hardship.
Topics: Dementia; Donepezil; Humans; Indans; Nootropic Agents; Piperidines; Prejudice; Randomized Controlled | 2007 |
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.
Topics: Acetylcholine; Animals; Brain; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Disease Mod | 2008 |
Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice.
Topics: Acetylcholinesterase; Animals; Avoidance Learning; Brain; Dementia; Disease Models, Animal; Donepezi | 2008 |
Summaries for patients. Drug treatment for patients with dementia: American College of Physicians and American Academy of Family Physicians recommendations.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excit | 2008 |
Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.
Topics: Activities of Daily Living; Affect; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Excit | 2008 |
Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia.
Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Brain; Celecoxib; Cyclooxygenase Inhibit | 2008 |
Dementia medications in palliative care #174.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Galantami | 2008 |
AAFP and ACP release guideline on dementia treatment.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Guidelines as Topic; Humans; Indans; Me | 2008 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Advertisements for donepezil. More convincing evidence of efficacy needs to be cited.
Topics: Advertising; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Industry; Humans; Indans; Piperidi | 1997 |
Advertisements for donepezil. National policy needs to be set for prescribing of this drug.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Health Policy; Humans; Indans; | 1997 |
Combination of risperidone and donepezil in Lewy body dementia.
Topics: Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy, Combinatio | 1998 |
Emerging antidementia drugs: a preliminary ethical view.
Topics: Aged; Alzheimer Disease; Beneficence; Cholinesterase Inhibitors; Dementia; Donepezil; Ethics, Medica | 1998 |
[50th Annual Meeting of the American Academy of Neurology (AAN). Minneapolis, 25 April--2 May 1998. 151st Annual Meeting of the American Psychiatric Association (APA). Toronto, 31 May--3 June 1998].
Topics: Alzheimer Disease; Dementia; Diagnosis, Differential; Donepezil; Humans; Indans; Neurology; Nootropi | 1998 |
Dementia with Lewy bodies: response of delirium-like features to donepezil.
Topics: Aged; Brain; Delirium; Dementia; Donepezil; Humans; Indans; Lewy Bodies; Magnetic Resonance Imaging; | 1998 |
Mania associated with donepezil.
Topics: Aged; Bipolar Disorder; Dementia; Donepezil; Drug Therapy, Combination; Female; Humans; Indans; Midd | 1998 |
Donepezil improves symptoms of delirium in dementia: implications for future research.
Topics: Aged; Alcohol Withdrawal Delirium; Cholinesterase Inhibitors; Cognition Disorders; Delirium; Dementi | 1998 |
Donepezil for dementia with Lewy bodies: a case study.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Hallucinations; Humans; Indans; Parkin | 1999 |
Guideline for primary care management of dementia. GPs may want to continue prescribing donepezil for patients.
Topics: Dementia; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 1999 |
Guideline for primary care management of dementia. Some recommendations given are not based directly on evidence cited.
Topics: Data Interpretation, Statistical; Dementia; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 1999 |
Treating visual hallucinations with donepezil.
Topics: Age Factors; Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Hallucinations; Humans; Indans; M | 1999 |
Comments on donepezil open label trial.
Topics: Cognition; Dementia; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 1999 |
Drugs for dementia: the first year. An audit of prescribing practice.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Drug Prescriptions; Drug Utilization; Follow-Up Stud | 2000 |
[Aphasia and dementia].
Topics: Aged; Aphasia, Primary Progressive; Atrophy; Brain; Dementia; Diagnosis, Differential; Donepezil; Fe | 2001 |
Donepezil management of schizophrenia with associated dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Comorbidity; Dementia; Donepezil; Drug Therapy, Co | 2002 |
Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease.
Topics: Bias; Cognition; Cross-Over Studies; Dementia; Donepezil; Effect Modifier, Epidemiologic; Humans; In | 2002 |
Use of anticholinergic medications by older adults with dementia.
Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Cholinergic Antagonists; Cholinesterase | 2002 |